Quantcast
Home > Quotes > SRNE
SRNE

Sorrento Therapeutics, Inc. Common Stock (SRNE) Quote & Summary Data

$2.57
*  
0.03
1.15%
Get SRNE Alerts
*Delayed - data as of Jul. 22, 2019  -  Find a broker to begin trading SRNE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SRNE Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
40
Today's High / Low
$ 2.64 / $ 2.54
Share Volume
866,144
50 Day Avg. Daily Volume
1,252,893
Previous Close
$ 2.60
52 Week High / Low
$ 6.875 / $ 1.80
Market Cap
336,582,838
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.69

Intraday Chart

Shares Traded

Share Volume:
866,144
50 Day Avg. Daily Volume:
1,252,893

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.41

Trading Range

The current last sale of $2.57 is 42.78% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.64 $ 6.875
 Low: $ 2.54 $ 1.80

Company Description (as filed with the SEC)

Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries (collectively, the "Company", "we", "us" and "our") is a clinical stage and commercial biopharma company focused on delivering innovative and clinically meaningful therapies to patients and their families, globally, to address unmet medical needs. We primarily focus on therapeutics areas in Immune-Oncology and Non-Opioid Pain Management. We also have programs assessing the use of our technologies and products in autoimmune, inflammatory and neurodegenerative diseases. At our core, we are an antibody-centric company and leverage our proprietary G-MAB(TM) library and targeted delivery modalities to generate the next generation of cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2 and CD137 among others.  ... More ...  



Risk Grade

Where does SRNE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.60
Open Date:
Jul. 22, 2019
Close Price:
$ 2.57
Close Date:
Jul. 22, 2019


Consensus Recommendation

Analyst Info